Glenmark bond: the right medicine for Indian HY?

Generic drug manufacturer takes advantage of rising order books for Indian high-yield deals to price significantly through many brokers' fair value estimates.

Glenmark bond: the right medicine for Indian HY?

Generic drug manufacturer Glenmark Pharmaceuticals executed a debut $200 million bond issue on Monday, taking advantage of rising demand for Indian high-yield deals to price significantly through brokers' fair value estimates. 

The BBBB rated deal represents the third Indian high-yield offering in the space of two months, following a $300 million issue for BB rated auto parts manufacturer Samvardhana Motherson Auto in mid-June and a $300 million issue for Ba3BB-BB...

To continue reading, please login or register for free

Click for more on: bonds | india | high yield | pharma | citi | hsbc | anz | barclays | dbs

Print Edition

FinanceAsia Print Edition

CONFERENCES

  • 2nd Compliance Summit Southeast Asia

    17 August 2017  |  Singapore
    The 2017 Compliance Summit Southeast Asia will take an in-depth look at the key compliance considerations today with a focus on regulation and new ...